Abstract: This disclosure relates to the genetic modification of DNMT3A gene in immune cells. In certain embodiments, the modified immune cells may be used in adoptive T cells therapies to enhance immune responses against cancer or chronic infections. In certain embodiments, the disclosure relates to deleting, changing, or inserting nucleotides within the DNMT3A gene in immune cells, e.g., human CD8 T cells, such that the DNMT3A gene product does not function for methylation. In certain embodiments, modification of the DNMT3A gene provides an improvement in antigen-specific T cells functions and/or an enhancement of the longevity of the cells.
Type:
Grant
Filed:
May 25, 2021
Date of Patent:
December 10, 2024
Assignees:
Emory University, St. Jude Children's Research Hospital, Inc.
Abstract: This disclosure relates to extracts from the Anacardiaceae (cashew plant family) and compositions comprising compounds contained therein. In certain embodiments, the extracts are derived from the fruit of a Schinus plant. In certain embodiments, the disclosure relates to methods of treating or preventing bacterial infections, acne, and other related uses.
Type:
Application
Filed:
August 5, 2024
Publication date:
November 28, 2024
Applicant:
Emory University
Inventors:
Cassandra L. Quave, James Lyles, Gina Porras-Brenes, Huaqiao Tang
Abstract: In certain embodiments, this disclosure relates to KRAS agonists, pharmaceutical composition, and uses in managing cancer. In certain embodiments, the KRAS agonist is 4-(4-(2-bromoacetamido)butyl)benzoic acid, salt, prodrug, or derivative thereof. In certain embodiments, this disclosure relates to methods of treating cancer comprising administering an effective amount of a compound of Formula I, salt, prodrug, or derivative thereof, to a subject in need thereof, wherein, substituents are reported herein.
Abstract: Aspects of the subject disclosure may include, for example, a non-transitory, machine-readable medium, comprising executable instructions that, when executed by a processing system including a processor, facilitate performance of operations including receiving a call; selecting a next carrier to handoff the call; generating a call data record (CDR) for the handoff to the next carrier; encrypting the CDR using a call encryption key, thereby creating an encrypted CDR; encrypting the encrypted CDR using a committee encryption key, thereby creating a double encrypted CDR; recording the double encrypted CDR to a blockchain; and sending the call encryption key to the next carrier. Other embodiments are disclosed.
Type:
Grant
Filed:
May 24, 2023
Date of Patent:
October 22, 2024
Assignees:
Emory University, AT&T Intellectual property I, L.P.
Abstract: A recombinant von Willebrand Factor (VWF) protein comprising one or more mutations and uses thereof are described. A recombinant protein complex comprising a von Willebrand factor sequence and one artificial Factor VIII sequence is described. A recombinant protein complex comprising a Factor VIII sequence and one artificial von Willebrand sequence is described. A recombinant protein complex is described that includes one artificial von Willebrand factor sequence and one artificial Factor VIII sequence. Also described are nucleic acid sequences and a vector encoding a VWF sequence and a pharmaceutical composition for inducing blood clotting that includes a VWF protein.
Type:
Grant
Filed:
November 1, 2018
Date of Patent:
October 15, 2024
Assignees:
Queen's University at Kingston, Kingston Health Sciences Centre, Emory University, Georgia Tech Research Corporation
Inventors:
Philip Zakas, David Lillicrap, Christopher Doering, Eric Gaucher, Caelan Radford, Harold Trent Spencer
Abstract: The systems, methods, and devices can efficiently express breast milk while being visually and audibly discreet, and portable. The breastmilk expression system for extracting milk from a breast of a female may include an interface configured to deliver suction to a nipple of the breast. The system may include a breastmilk storage container configured to store breastmilk. The system may include a control device operatively coupled to the breastmilk storage container and the interface. The control device may include one or more pressure reservoirs configured to store negative pressure. The control device may be configured to cause passive suction at the interface to cause extraction of the breast milk by controlling delivery of the negative pressure stored in the one or more pressure reservoirs to the interface.
Type:
Grant
Filed:
February 20, 2019
Date of Patent:
September 24, 2024
Assignee:
Emory University
Inventors:
Andrea Braden Joyner, David Andrew Barr
Abstract: This disclosure relates to VIP antagonist for uses in managing the treatment or prevention of cancer and viral infections. In certain embodiments, this disclosure relates to chimeric variants of VIP antagonists, as peptides disclosed herein, and pharmaceutical composition comprising the same. In certain embodiments, this disclosure contemplates methods of stimulating immune cells to target cancer by mixing immune cells in vitro with peptides disclosed herein and further administering an effective amount of stimulated immune cells to a subject in need of cancer treatment.
Type:
Grant
Filed:
November 15, 2019
Date of Patent:
September 24, 2024
Assignee:
Emory University
Inventors:
Edmund K. Waller, Yiwen Li, Sruthi Ravindranathan, Jian-Ming Li
Abstract: This disclosure relates to extracts from the Anacardiaceae (cashew plant family) and compositions comprising compounds contained therein. In certain embodiments, the extracts are derived from the fruit of a Schinus plant. In certain embodiments, the disclosure relates to methods of treating or preventing bacterial infections, acne, and other related uses.
Type:
Application
Filed:
March 14, 2023
Publication date:
September 19, 2024
Applicant:
Emory University
Inventors:
Cassandra L. Quave, James Lyles, Gina Porras-Brenes, Huaqiao Tang
Abstract: This disclosure relates to peptides and nanoparticles comprising a surface molecule that binds or blocks PD-L1. In certain embodiments, the disclosure relates to methods of using peptides or nanoparticles disclosed herein for the treatment of cancer. In certain embodiments, the disclosure relates to methods of using nanoparticles disclosed herein for therapeutic and diagnostic applications.
Abstract: It is disclosed herein that ssAAV and scAAV vectors of the same serotype administered by injection into the cerebrospinal fluid (CSF) via the intracerebroventricular (ICV) or intrathecal (cisternal or lumbar) route exhibit different cellular tropisms in the central nervous system. Thus, a subject can be treated by injection into the CSF of ssAAV or scAAV vector encoding a therapeutic protein, such as an ssAAV9 or scAAV9 vector. The therapeutic protein can be targeted to specific cells using these vectors. In some embodiments, scAAV9 is utilized to achieve superior transduction in the hippocampus, cerebellum and cerebral cortex where both neurons, particularly Purkinje neurons, and glial cells (such as astrocytes) are transduced. In other embodiments, ssAAV9 is utilized to minimize transduction of astrocytes. In further embodiments, an immunosuppressive agent is also administered to the subject.
Type:
Grant
Filed:
January 25, 2017
Date of Patent:
August 27, 2024
Assignees:
Emory University, REGENXBIO. Inc.
Inventors:
Anthony Donsante, Karen Kozarsky, Nicholas Matthew Boulis, Jonathan Patrick Riley
Abstract: Systems and methods provide a parallelized deep learning approach to spectral fitting for magnetic resonance spectroscopy data enabling accurate and rapid spectral fitting and determination of metabolite measurements using a conventional computer. The method may include processing multi-spectra magnetic resonance (MR) spectroscopy data of a region of interest through a series of neural networks. The method may include determining baseline components of each spectrum using a first neural network of the series, generating baseline-corrected components for each spectrum using the baseline components; and determining one or more peak components of each spectrum using a second neural network of the series and the baseline-corrected components. The method may further include determining one or more metabolite measurements of the one or more metabolites in the region of interest using the one or more peak components.
Type:
Grant
Filed:
November 20, 2019
Date of Patent:
August 20, 2024
Assignees:
Emory University, University of Miami
Inventors:
Hyunsuk Shim, Lee Cooper, Saumya Gurbani, Andrew Maudsley, Sulaiman Sheriff
Abstract: Methods and systems for monitoring of sensor data for processing by machine-learning models to generate event predictions to estimate a risk a medical event are provided. An electronic device or wearable smart device may monitor the output of various sensors to collect data related to a person's activity level, location changes, and communications and may use this information as input to a personalized trained machine-learning model to predict a likelihood of an event.
Type:
Grant
Filed:
December 5, 2019
Date of Patent:
August 6, 2024
Assignees:
Emory University, Georgia Tech Research Foundation
Inventors:
Gari Clifford, Ayse Cakmak, Amit Shah, Erik Reinertsen
Abstract: Disclosed are acyclic nucleoside prodrugs with improved metabolic stability and oral bioavailability. In general, the prodrugs are derivatives of acyclic nucleoside phosphonates containing a lipid-like moiety that can increase oral absorption and subsequent stability in the liver and plasma. Preferably, the lipid-like moiety can resist enzyme-mediated ?-oxidation, such as ?-oxidation catalyzed by cytochrome P450 enzymes. Also disclosed are pharmaceutical formulations of the acyclic nucleoside prodrugs. The acyclic nucleoside prodrugs and pharmaceutical formulations thereof can be used to treat viral infections, such as HIV infections, and/or viral-associated cancer, such as HPV-associated cancers.
Type:
Grant
Filed:
August 24, 2020
Date of Patent:
July 30, 2024
Assignee:
Emory University
Inventors:
Eric Miller, Nicole Pribut, Michael D'Erasmo, Madhuri Dasari, Kyle Giesler, Sabrina Iskandar, Dennis C. Liotta
Abstract: Compounds, compositions and methods for preventing, treating or curing a coronavirus infection in human subjects or other animal hosts. In one embodiment, the compounds can be used to treat an infection with a severe acute respiratory syndrome virus, such as human coronavirus 229E, SARS, MERS, SARS-CoV-1, OC43, and SARS-CoV-2. In another embodiment, the methods are used to treat a patient infected with a Flavivirus, Picornavus, Togavirus, or Bunyavirus.
Type:
Application
Filed:
April 11, 2022
Publication date:
July 4, 2024
Applicant:
Emory University
Inventors:
Raymond SCHINAZI, Franck AMBLARD, Zhe CHEN, Keivan ZANDI
Abstract: In some embodiments, described herein is a method of tumor treatment or tumor vaccination. The method generally comprises applying to a human being in need thereof a tumor therapeutic composition or tumor vaccine defined herein. The tumor therapeutic composition or tumor vaccine can be produced by protein transfer of glycosyl-phosphatidylinositol (GPI)-anchored immunostimulatory or costimulatory molecules.
Abstract: Among the various aspects of the present disclosure is the provision for systems and methods for individualized targeting of deep brain stimulation (DBS). In addition, methods for monitoring the treatment of a subject using a DBS system are described.
Type:
Application
Filed:
December 1, 2023
Publication date:
June 27, 2024
Applicants:
Washington University, The Regents of the University of Michigan, Emory University
Inventors:
Peter Brunner, Markus Adamek, Jon Willie, Eric Leuthardt, Enrico Opri, Svjetlana Miocinovic
Abstract: Disclosed herein are compounds having antiviral activity, and, in particular, an inhibitory activity on the replication of Respiratory Syncytial Virus (RSV). Druggable target sites, including Px, in the RSV N protein are disclosed, as well as compounds targeting Px. The compounds can be used to treat patients with RSV infection.
Type:
Grant
Filed:
May 3, 2019
Date of Patent:
June 25, 2024
Assignees:
Georgia State University Research Foundation, Inc., Emory University
Inventors:
Richard Plemper, Julien Sourimant, Edgars Jecs, Dennis Liotta, Stephen Pelly, Robert Wilson, Zackery Will Dentmon
Abstract: The present disclosure provides novel cell compositions engineered to express at least a chimeric antigen receptor and a survival factor. Methods of using such cell compositions are also described.
Type:
Grant
Filed:
September 6, 2016
Date of Patent:
June 11, 2024
Assignees:
The UAB Research Foundation, Emory University, Children's Healthcare of Atlanta, Inc.
Inventors:
Lawrence S. Lamb, H. Trent Spencer, G. Yancey Gillespie
Abstract: The disclosure relates thieno[2,3-d]pyrimidin-4-one derivatives as modulators of NMDA receptors and uses related thereto. In certain embodiments, the disclosure relates to pharmaceutical compositions comprising compounds disclosed herein or pharmaceutically acceptable salts or prodrugs thereof. In certain embodiments, the compositions disclosed herein are used for managing conditions related to cognition, typically prevention or treatment of neurological conditions related to the NMDA receptor.
Type:
Grant
Filed:
November 18, 2015
Date of Patent:
June 11, 2024
Assignee:
Emory University
Inventors:
Stephen F. Traynelis, Lanny S. Liebeskind, Dennis C. Liotta, Ethel C. Garnier-Amblard, PavanKumar Reddy Gangireddy
Abstract: Disclosed are compounds to the treatment of infectious diseases and methods of treating such diseases. The compounds are derivatives of clevudine.